Patent: 9,056,126
✉ Email this page to a colleague
Summary for Patent: 9,056,126
| Title: | Hydrogel formulations |
| Abstract: | A polymeric prodrug composition including a hydrogel, a biologically active moiety and a reversible prodrug linker. The prodrug linker covalently links the hydrogel and the biologically active moiety at a position and the hydrogel has a plurality of pores with openings on its surface. The diameter of the pores is larger than that of the biologically active moiety at least at all points of the pore between at least one of the openings and the position of the biologically active moiety. |
| Inventor(s): | Hersel; Ulrich (Heidelberg/Hanschuhsheim, DE), Rau; Harald (Heidelberg, DE), Schnepf; Robert (Heidelberg/Dossenheim, DE), Vetter; Dirk (Heidelberg/Neuenheim, DE), Wegge; Thomas (Heidelberg/Ziegelhausen, DE) |
| Assignee: | ASCENDIS PHARMA A/S (Hellerup, DK) |
| Application Number: | 13/111,777 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,056,126
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Ferring Pharmaceuticals Inc. | NOVAREL | chorionic gonadotropin | For Injection | 017016 | 01/15/1974 | ⤷ Try a Trial | 2024-07-05 |
| Ferring Pharmaceuticals Inc. | NOVAREL | chorionic gonadotropin | For Injection | 017016 | 12/27/1984 | ⤷ Try a Trial | 2024-07-05 |
| Ferring Pharmaceuticals Inc. | NOVAREL | chorionic gonadotropin | For Injection | 017016 | 02/15/1985 | ⤷ Try a Trial | 2024-07-05 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
